期刊文献+

奥扎格雷联合血塞通注射液治疗冠心病心绞痛疗效观察 被引量:4

OZAGERAL AND XUESETONG INJECTION IN TREATING CORONARY ANGINA PECTORIS
下载PDF
导出
摘要 目的观察扎格雷和血塞通注射液治疗冠心病心绞痛的疗效。方法将296例冠心病心绞痛患者随机分为两组,对照组给予硝酸酯类、β-受体阻滞剂(-βB)、阿司匹林等治疗;治疗组在此基础上加奥扎格雷80 mg,静脉滴注,1次/d,5%葡萄糖200 ml加血塞通注射液20 ml,静脉滴注,3次/d,连用2周。结果显效率治疗组为64.9%,对照组为48.6%;总有效率治疗组为93.2%,对照组为79.7%。两组的显效率和总有效率比较,均有显著差异(P<0.01)。结论奥扎格雷与血塞通注射液联合应用治疗冠心病心绞痛,能明显提高疗效。 Objective To observe the curative effects of ozagral and xuesetong injection in treating coronary anagina pectoris. Methods 296 cases were randomly divided into two groups. The contrast group was treated with nirtrate esters, β-receptor blocking agent and aspirin, while the treatment group were given 80 mg of ozagral once a day and 200ml of 5 % glucose plus 20ml of ozagral three times a day for two weeks besides the therapy in the contrast group. Results The obvious effective rates and the total effective rates were 64.9 % and 93.2 % in the treatment group and 48.6% and 79.7% in the contreast group respectively( P≤0.01). Conclusion Ozagral and xuesetong injection can be used to treat coronary angina pectoris with good therapeutic effect.
作者 郁秀芹
机构地区 莒南县人民医院
出处 《山东医学高等专科学校学报》 2008年第1期51-52,共2页 Journal of Shandong Medical College
关键词 奥扎格雷 血塞通注射液 冠心病 心绞痛 Ozagral Xuesetong injection Coronary heart disease Angina pectoris
  • 相关文献

参考文献4

二级参考文献20

  • 1屈晓冰,孙振球,陈美娟,陈珑珑.冠心病患者P-选择素水平及其与冠状动脉病变程度间的关系[J].中华流行病学杂志,2005,26(8):617-621. 被引量:33
  • 2Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies : Part I. Circulation, 2003,108 : 1664-1672.
  • 3Shebuski R J, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther, 2002,300 : 729-735.
  • 4Carter AM, Anagnostopoulou K, Mansfield MW, et al. Soluble P-selectin levels, P-selectin polyrnorphisms and cardiovascular disease. J Thromb Haemost,2003,1 : 1718-1723.
  • 5Braunwald E, Antman EM, Beasley JW, et ah ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2000, 36:970-1062.
  • 6Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983,51 : 606.
  • 7Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( committee to revise the 1993 guidelines for percutaneous translurninal coronary angioplasty ). J Am Coll Cardiol,2001,37 : 2215-2239.
  • 8Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest, 1997, 99 :1037-1040.
  • 9Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advance atherosclerosis in apoE-deficient mice.Circulation, 2000,101:2290-2295.
  • 10Phillips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand 1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient Mice. Circulation,2003,107 : 2244-2249.

共引文献70

同被引文献89

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部